156 related articles for article (PubMed ID: 26360058)
41. B-cell precursor acute lymphoblastic leukemia and stromal cells communicate through Galectin-3.
Fei F; Joo EJ; Tarighat SS; Schiffer I; Paz H; Fabbri M; Abdel-Azim H; Groffen J; Heisterkamp N
Oncotarget; 2015 May; 6(13):11378-94. PubMed ID: 25869099
[TBL] [Abstract][Full Text] [Related]
42. Magnolin Inhibits Proliferation and Invasion of Breast Cancer MDA-MB-231 Cells by Targeting the ERK1/2 Signaling Pathway.
Wang J; Zhang S; Huang K; Shi L; Zhang Q
Chem Pharm Bull (Tokyo); 2020; 68(5):421-427. PubMed ID: 32378540
[TBL] [Abstract][Full Text] [Related]
43. Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition.
Irving J; Matheson E; Minto L; Blair H; Case M; Halsey C; Swidenbank I; Ponthan F; Kirschner-Schwabe R; Groeneveld-Krentz S; Hof J; Allan J; Harrison C; Vormoor J; von Stackelberg A; Eckert C
Blood; 2014 Nov; 124(23):3420-30. PubMed ID: 25253770
[TBL] [Abstract][Full Text] [Related]
44. Activation of the mitogen-activated protein kinase-extracellular signal-regulated kinase pathway in childhood B-cell acute lymphoblastic leukemia.
Pillai PM; Mallory N; Pierro J; Saliba J; Newman D; Hu J; Bhatla T; Raetz E; Carroll WL; Evensen NA
Pediatr Blood Cancer; 2022 Oct; 69(10):e29771. PubMed ID: 35593589
[TBL] [Abstract][Full Text] [Related]
45. Overcoming Microenvironment-Mediated Chemoprotection through Stromal Galectin-3 Inhibition in Acute Lymphoblastic Leukemia.
Tarighat SS; Fei F; Joo EJ; Abdel-Azim H; Yang L; Geng H; Bum-Erdene K; Grice ID; von Itzstein M; Blanchard H; Heisterkamp N
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830047
[TBL] [Abstract][Full Text] [Related]
46. Influence of Casein kinase II inhibitor CX-4945 on BCL6-mediated apoptotic signaling in B-ALL in vitro and in vivo.
Richter A; Sender S; Lenz A; Schwarz R; Hinz B; Knuebel G; Sekora A; Murua Escobar H; Junghanss C; Roolf C
BMC Cancer; 2020 Mar; 20(1):184. PubMed ID: 32131762
[TBL] [Abstract][Full Text] [Related]
47. RAS pathway mutations as a predictive biomarker for treatment adaptation in pediatric B-cell precursor acute lymphoblastic leukemia.
Jerchel IS; Hoogkamer AQ; Ariës IM; Steeghs EMP; Boer JM; Besselink NJM; Boeree A; van de Ven C; de Groot-Kruseman HA; de Haas V; Horstmann MA; Escherich G; Zwaan CM; Cuppen E; Koudijs MJ; Pieters R; den Boer ML
Leukemia; 2018 Apr; 32(4):931-940. PubMed ID: 28972594
[TBL] [Abstract][Full Text] [Related]
48. CREBBP knockdown enhances RAS/RAF/MEK/ERK signaling in Ras pathway mutated acute lymphoblastic leukemia but does not modulate chemotherapeutic response.
Dixon ZA; Nicholson L; Zeppetzauer M; Matheson E; Sinclair P; Harrison CJ; Irving JA
Haematologica; 2017 Apr; 102(4):736-745. PubMed ID: 27979926
[TBL] [Abstract][Full Text] [Related]
49. Inhibition of DNA-PK enhances chemosensitivity of B-cell precursor acute lymphoblastic leukemia cells to doxorubicin.
Alikarami F; Safa M; Faranoush M; Hayat P; Kazemi A
Biomed Pharmacother; 2017 Oct; 94():1077-1093. PubMed ID: 28821159
[TBL] [Abstract][Full Text] [Related]
50. Analysis of acute lymphoblastic leukemia drug sensitivity by changes in impedance via stromal cell adherence.
Luong A; Cerignoli F; Abassi Y; Heisterkamp N; Abdel-Azim H
PLoS One; 2021; 16(9):e0258140. PubMed ID: 34591931
[TBL] [Abstract][Full Text] [Related]
51. Ex vivo modelling of drug efficacy in a rare metastatic urachal carcinoma.
Mäkelä R; Arjonen A; Härmä V; Rintanen N; Paasonen L; Paprotka T; Rönsch K; Kuopio T; Kononen J; Rantala JK
BMC Cancer; 2020 Jun; 20(1):590. PubMed ID: 32576176
[TBL] [Abstract][Full Text] [Related]
52. Sensitization to Drug Treatment in Precursor B-Cell Acute Lymphoblastic Leukemia Is Not Achieved by Stromal NF-κB Inhibition of Cell Adhesion but by Stromal PKC-Dependent Inhibition of ABC Transporters Activity.
Ruiz-Aparicio PF; Uribe GI; Linares-Ballesteros A; Vernot JP
Molecules; 2021 Sep; 26(17):. PubMed ID: 34500796
[TBL] [Abstract][Full Text] [Related]
53. The role of the RAS pathway in iAMP21-ALL.
Ryan SL; Matheson E; Grossmann V; Sinclair P; Bashton M; Schwab C; Towers W; Partington M; Elliott A; Minto L; Richardson S; Rahman T; Keavney B; Skinner R; Bown N; Haferlach T; Vandenberghe P; Haferlach C; Santibanez-Koref M; Moorman AV; Kohlmann A; Irving JA; Harrison CJ
Leukemia; 2016 Sep; 30(9):1824-31. PubMed ID: 27168466
[TBL] [Abstract][Full Text] [Related]
54. Development of ERK1/2 inhibitors as a therapeutic strategy for tumour with MAPK upstream target mutations.
Miao L; Tian H
J Drug Target; 2020 Feb; 28(2):154-165. PubMed ID: 31340679
[TBL] [Abstract][Full Text] [Related]
55. Tight regulation of FOXO1 is essential for maintenance of B-cell precursor acute lymphoblastic leukemia.
Wang F; Demir S; Gehringer F; Osswald CD; Seyfried F; Enzenmüller S; Eckhoff SM; Maier T; Holzmann K; Debatin KM; Wirth T; Meyer LH; Ushmorov A
Blood; 2018 Jun; 131(26):2929-2942. PubMed ID: 29622548
[TBL] [Abstract][Full Text] [Related]
56. Interleukin-7 receptor α mutational activation can initiate precursor B-cell acute lymphoblastic leukemia.
Almeida ARM; Neto JL; Cachucho A; Euzébio M; Meng X; Kim R; Fernandes MB; Raposo B; Oliveira ML; Ribeiro D; Fragoso R; Zenatti PP; Soares T; de Matos MR; Corrêa JR; Duque M; Roberts KG; Gu Z; Qu C; Pereira C; Pyne S; Pyne NJ; Barreto VM; Bernard-Pierrot I; Clappier E; Mullighan CG; Grosso AR; Yunes JA; Barata JT
Nat Commun; 2021 Dec; 12(1):7268. PubMed ID: 34907175
[TBL] [Abstract][Full Text] [Related]
57. DNMT1 expression partially dictates 5-Azacytidine sensitivity and correlates with RAS/MEK/ERK activity in gastric cancer cells.
Chen Z; Zhang L; Yang Y; Liu H; Kang X; Nie Y; Fan D
Epigenetics; 2023 Dec; 18(1):2254976. PubMed ID: 37691391
[TBL] [Abstract][Full Text] [Related]
58. Glucocorticoids and selumetinib are highly synergistic in RAS pathway-mutated childhood acute lymphoblastic leukemia through upregulation of BIM.
Matheson EC; Thomas H; Case M; Blair H; Jackson RK; Masic D; Veal G; Halsey C; Newell DR; Vormoor J; Irving JAE
Haematologica; 2019 Sep; 104(9):1804-1811. PubMed ID: 30655370
[TBL] [Abstract][Full Text] [Related]
59. Selumetinib: a selective MEK1 inhibitor for solid tumor treatment.
Hedayat M; Jafari R; Majidi Zolbanin N
Clin Exp Med; 2023 Jun; 23(2):229-244. PubMed ID: 35171389
[TBL] [Abstract][Full Text] [Related]
60. A high throughput assay to identify substrate-selective inhibitors of the ERK protein kinases.
Miller CJ; Muftuoglu Y; Turk BE
Biochem Pharmacol; 2017 Oct; 142():39-45. PubMed ID: 28647489
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
